|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Complete response to exemestane in a patient with a desmoid tumor 显示文摘 | Debled M Le Loarer F Callonnec F | 2012 | Future Oncol2012，8，4： | 1 |
| 2 | Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma显示文摘 | Antonescu CR Le Loarer F Mosquera JM | 2013 | Genes Chromosomes Cancer2013，52，8： | 1 |
| 3 | 查看详情显示文摘 | Ekedahl A Rantamaki K Goniche M Mailloux J Petrzilka V Alper B Baranov Y Basiuk V Beaumont P Corrigan G Delpech L Erents K Granucci G Hawkes N Hobirk J Imbeaux F Joffrin E Kirov K Loarer T McDonald D Nave M F F Nunes I Ongena J Parail V Piccolo F Rachlew | | 0，，： | 1 |
| 4 | Gene expression profiling improves prognostication by nomogram in patients with soft-tissue sarcomas显示文摘Dear Editor,Surgery remains the cornerstone of treatment for softtissue sarcomas(STS)[1].However,despite adequate locoregional treatment,30%-40%of the patients eventually develop metastases[2,3].Accurate risk assessment is crucial to tailor therapeutic strategies and to identify high-risk patients who may benefit from perioperative chemotherapy.Hence,several efforts have been made to develop prognostic nomograms that enable individual prognosis prediction;representing an important decision-making aid for oncologists and surgeons involved in sarcoma care[4-6]. | Amandine Crombé Mariella Spalato-Ceruso Audrey Michot Yech’an Laizet Carlo Lucchesi Maud Toulmonde Kevin Bourcier Francois Le Loarer Antoine Italiano | 2022 | Cancer Communications2022，42，6： | 0 |
| 5 | Prognostic impact of circulating tumor cells in patients with soft-tissue sarcomas:a prospective study显示文摘Dear Editor,Sarcomas represent a heterogenous group of tumors accounting for about 1%of cancer in adults and 15%in children[1].However,despite adequate locoregional treatment,up to 40%of patients develop metastatic disease.Drugs used in the advanced setting have very limited efficacy,with a response rate of<10%and progression-free survival of<4 months and are mainly used for palliative purposes[1].It is,therefore,important to monitor individual therapy responses to avoid inefficient therapy and unnecessary toxicity.Such monitoring is currently based on repeated CT imaging which may represent an important burden for patients with advanced disease[2]. | Julie Blanchi Audrey Laroche-Clary Francois Le Loarer Benjamin Bonhomme Antoine Italiano | 2023 | Cancer Communications2023，43，3： | 0 |
| 6 | 一种CIC融合肉瘤家族的新分子亚型:CIC-NUTM1基因融合肉瘤的临床病理特征显示文摘CIC基因融合肉瘤是一种新发现的肿瘤家族,该肿瘤长期以来与尤因肿瘤家族联系在一起,但其独特之处在于具有CIC基因融合。3'端融合配对包括DUX4、FOXO4以及最近强调的NUTM1。 | 张曲霞(摘译) 许春伟(审校) Le Loarer F Pissaloux D Watson S | 2021 | 临床与实验病理学杂志2021，37，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员